Lymphomas in patients with neurofibromatosis type 1 (NF1): another malignancy in the NF1 syndrome?
Pathology · 2023
DOI: 10.1016/j.pathol.2023.01.002 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pathology, 2023. Verfasst von Faiha Fareez und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Molecular Medicine, Hamilton, Ontario, Canada. Hauptthemen laut MEDLINE: Neurofibromatosis 1, Lymphoma, Skin Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 154 Literaturangaben.
Abstract (Originalsprache)
Neurofibromatosis type 1 (NF1) is an autosomal dominant multisystem syndrome caused by mutations in the neurofibromin 1 (NF1) gene that encodes for the protein neurofibromin acting as a tumour suppressor. Neurofibromin functions primarily as a GTPase-activating protein for the Ras family of oncogenes, which activates many signalling pathways for cell proliferation and differentiation; without neurofibromin, Ras is constitutively activated, thereby turning on many downstream signalling pathways related to oncogenesis. Patients with NF1 have a well known predisposition for certain types of malignancies including malignant peripheral nerve sheath tumours, gliomas, and breast cancers, as well as a potential association of NF1 with lymphoproliferative disorders such as lymphomas. In this article, we review the pathophysiology and tumourigenesis of NF1, previously reported cases of cutaneous lymphomas in NF1 patients along with our case demonstration of a NF1-associated scalp B-cell lymphoma, and NF1-associated extra cutaneous lymphomas. The diagnosis of lymphomas particularly cutaneous lymphomas may be difficult in NF1 patients as they often have skin lesions and/or cutaneous/subcutaneous nodules or tumours like neurofibromas, which raises the possibility of underdiagnosed cutaneous lymphomas in NF1 patients. We also comprehensively discuss the association between NF1 and lymphomas. In summary, most studies support a potential association between NF1 and lymphomas. Further investigation is needed to clarify the association between NF1 and lymphomas in order to bring clinical awareness of possibly underdiagnosed NF1-associated lymphomas and individualised management of NF1 patients to practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology and Molecular Medicine, Hamilton, Ontario, Canada.
- Department of Surgery/Neurosurgery, McMaster University, Hamilton, Ontario, Canada.
- Department of Laboratory Medicine and Pathobiology/Hematopathology, University of Toronto, Toronto, Ontario, Canada.
- Department of Pathology and Molecular Medicine, Hamilton, Ontario, Canada; Department of Pathology and Molecular Medicine/Neuropathology, Hamilton General Hospital, Hamilton, Ontario, Canada. Electronic address: luj85@m…
Zitieren
APA
Fareez, F., Wang, B. H., Brain, I., & Lu, J. Q. (2023). Lymphomas in patients with neurofibromatosis type 1 (NF1): another malignancy in the NF1 syndrome?. Pathology. https://doi.org/10.1016/j.pathol.2023.01.002
Vancouver
Fareez F, Wang BH, Brain I, Lu JQ. Lymphomas in patients with neurofibromatosis type 1 (NF1): another malignancy in the NF1 syndrome?. Pathology. 2023. doi:10.1016/j.pathol.2023.01.002
BibTeX
@article{Fareez2023,
author = {Fareez, Faiha and Wang, Bill H and Brain, Ian and Lu, Jian-Qiang},
title = {Lymphomas in patients with neurofibromatosis type 1 (NF1): another malignancy in the NF1 syndrome?},
journal = {Pathology},
year = {2023},
doi = {10.1016/j.pathol.2023.01.002}
}
EUVIMED